| 8 -0.8 (-9.09%) | 01-14 11:18 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.65 |
1-year : | 12.18 |
| Resists | First : | 9.11 |
Second : | 10.43 |
| Pivot price | 8.01 |
|||
| Supports | First : | 7 |
Second : | 5.82 |
| MAs | MA(5) : | 8.12  |
MA(20) : | 8 |
| MA(100) : | 8.56 |
MA(250) : | 8.25 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44.9 |
D(3) : | 40.3 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 12.05 | Low : | 6.51 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADXN ] has closed above bottom band by 48.9%. Bollinger Bands are 42.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.44 - 10.48 | 10.48 - 10.52 |
| Low: | 6.93 - 6.96 | 6.96 - 6.99 |
| Close: | 8.73 - 8.8 | 8.8 - 8.86 |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Wed, 07 Jan 2026
Addex Therapeutics (ADXN) Advances NTX-253 into Clinical Trials for Schizophrenia - GuruFocus
Wed, 07 Jan 2026
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia - marketscreener.com
Mon, 05 Jan 2026
Avoiding Lag: Real-Time Signals in (ADXN) Movement - Stock Traders Daily
Thu, 11 Dec 2025
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. - The Manila Times
Thu, 04 Dec 2025
Earnings Scheduled For December 4, 2025 - Addex Therapeutics (NASDAQ:ADXN), Argan (NYSE:AGX) - Benzinga
Thu, 04 Dec 2025
Earnings call transcript: Addex Therapeutics Q3 2025 sees stock dip post-earnings - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 9.386e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 4 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.46e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 403.5 % |
| Return on Equity (ttm) | -15.9 % |
| Qtrly Rev. Growth | 158540 % |
| Gross Profit (p.s.) | -7.15 |
| Sales Per Share | -34.69 |
| EBITDA (p.s.) | -250310 |
| Qtrly Earnings Growth | -9.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.24 |
| Price to Cash Flow | 280 |
| Dividend | 0 |
| Forward Dividend | 9600 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|